Key Takeaways
- Volume-driven revenue drop, margin held: Revenue fell on a 90% volume decline, mostly from ATBS destocking in oil & gas, yet EBITDA margin stayed near 28% because dollar-per-kg spreads held firm.
- ATBS destocking is a six-month anomaly: Customers overbought post-COVID and are now working down inventory; management expects recovery from October, and the long-term demand thesis for the 40,000-to-60,000 MTPA expansion is intact.
- New products are the FY24 growth bridge: The VAPL merger plus new antioxidants are expected to contribute ₹150–175 crores this year, offsetting ATBS weakness and keeping full-year sales near ₹2,000 crores.
- Margins guided lower for the full year: Management expects full-year margins below 28% as the mix shifts toward lower-margin butyl phenols and antioxidants, even as absolute dollar spreads hold.
- What to watch next quarter: Whether the October ATBS recovery materializes on schedule, the NCLT merger approval timeline, and any capex announcement for the Anisole/MEHQ/Guaiacol chemistry pipeline.
ATBS: The Destocking Drag & Recovery Bet
- Volume, not price, did the damage: 90% of the Q1 revenue decline was volume-driven, with only 10% from price; management maintained ~28% EBITDA margins despite the drop because raw material costs for ATBS did not decline much and contract formulas held.
- Root cause is post-COVID inventory overhang: Oil & gas customers over-purchased during supply chain panic, built excessive inventory, and are now destocking; management was told in March the process would take six months, placing recovery from October onwards.
- Competitive position appears unchanged: Management has not seen any product from any other Indian manufacturer in the market yet, suggesting the destocking is a demand-side event rather than a share loss.
- Expansion still on, anchored to long-term demand: The new ATBS line taking capacity from 40,000 to 60,000 MTPA is scheduled to complete by early next fiscal or end of FY2024, when demand is expected to normalize; the five-to-ten-year outlook from oil & gas and other segments remains strong.
- Pricing resets with a quarterly lag: If raw material prices fall in Q1, the effect flows through in Q2; however, MTB, the largest raw material, has not declined, so there has not been much price correction.
Vinati Saraf Mutreja: "We were told that in March that six months the destocking will go on. So I expect some recovery from October onwards."
New Products: The FY24 Bridge
- VAPL is now commercial and contributing: VAPL has started commercial production and sales, with expected revenues of ~₹150 crores this year; the amalgamation awaits final NCLT approval, and management is committed to bringing the asset into VOL even if the merger route stalls.
- Antioxidants add another layer: New product revenue guidance for FY2024 is ₹150 to ₹175 crores, with antioxidants forming a material part; current demand pressure on AOs is described as transient, with a strong long-term outlook.
- Butyl phenols plus antioxidants is a ₹900–1,000 crore revenue pool: External sales of butyl phenol are around ₹300 crores and external antioxidants around ₹600 crores; combined, the basket carries an EBITDA margin of 15% to 20%, lower than the corporate average.
- Product mix is shifting this year: ATBS stays at ~40% of sales, IBB at ~20%, butyl phenols at ~17%; as ATBS recovers, butyl phenols share will also rise, and AOs will begin adding to the mix post-amalgamation.
Margins: Spreads Hold, But Mix Dilutes the Percentage
- The metric that matters is dollar per kg, not margin %: Management considers margin as a percentage of sales irrelevant because prices fluctuate; what is fixed is the dollar-per-kg spread, so margin % rises when prices are low and falls when raw material costs climb.
- Full-year margin guided below Q1's 28%: The mix shift toward butyl phenols and antioxidants, which carry lower margins, will pull the blended number down; management declined to give a specific figure but said to take below 28%.
- IBB held up well: Sales picked up in FY2023 and continued well in Q1; one Indian competitor exited the business, so margin impact has been minimal, and raw material fluctuations are passed on to customers.
Vinati Saraf Mutreja: "Margin as a percentage of sales is very irrelevant because prices also fluctuate, when the price is low, what is fixed really the dollar per kg. So margin as a percentage of sales increases, but in a high price environment when RMCs are increasing margin as a percentage of sales comes down."
Pipeline: Anisole, MEHQ & Guaiacol Chemistry
- Next growth leg is in R&D: The company is working on niche, lower-volume, higher-value antioxidants and products under the Anisole/MEHQ/Guaiacol basket; no capex has been announced yet, and further investment will be disclosed once trials are complete.
- Initial market share target of 25–30%: Management expects to capture roughly a quarter to a third of the addressable market for these chemistries.
- Cost-effective process route: The pathway runs phenol plus methanol to Anisole, then to MEHQ and Guaiacol; management described it as cost-effective but did not clarify whether the technology is uniquely developed or comparable to competitors'.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| ATBS destocking recovery | Recovery from October onwards, per customer indications of six-month destocking from March | Q3 FY24 |
| Full-year sales | Close at around ₹2,000 crores, with ~₹150 crores from antioxidants, provided the merger goes through | FY24 |
| Next-year sales growth | 20% to 25% growth, driven by ATBS recovery plus AO and butyl phenol pickup | FY25 |
| Next-year antioxidant business | Double to ~₹300 crores in sales | FY25 |
| Q2 performance | Similar to Q1 | Q2 FY24 |
| Full-year margin | Below 28% | FY24 |
| ATBS capacity expansion | New line from 40,000 to 60,000 MTPA complete | End of FY24 or early FY25 |
| VOPL plant commissioning | Commissioned | Around March 2024 |
| Solar power expansion | Additional 11 MW commissioned | September 2023 |
| NCLT merger approval | Approval hoped for before December; if not, alternative routes include withdrawing the scheme and doing an acquisition or leasing the plant | Before December 2023 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue from operations | ₹430 cr, vs ~₹500 cr in Q1 FY23 |
| EBITDA | ₹109 cr, declined 15% to 17% YoY |
| PAT | Declined 15% to 17% YoY |
| EBITDA margin | ~28%, maintained even in Q1 |
| Revenue decline attribution | 90% due to lower volumes, 10% due to prices |
| ATBS revenue share | ~40% of total revenue |
| IBB revenue share | ~20% of total revenue |
| Butyl phenols revenue share | ~17% of total revenue |
| VAPL (antioxidants) plant utilization | ~25% of capacity |
| VAPL expected revenue for FY24 | ~₹150 cr |
| FY24 revenue guidance (with merger) | ~₹2,000 cr, including ~₹150 cr from antioxidants |
| FY25 expected sales growth | 20% to 25%, with AO pickup, butyl phenol pickup, ATBS recovery |
| Full year FY24 margin guidance | Below 28%, conservative due to lower-margin butyl phenols and AOs |
| ATBS capacity expansion | From 40,000 to 60,000 metric tons per annum, completion expected end of FY24 or early next fiscal |
| VOPL capex | ~₹260 cr for MEHQ, Guaiacol, Iso Amylene derivatives, Anisoles; commissioning by March 2024 |